ChiCTR1900021998
正在进行
/
/
/
2019-03-19
/
/
青光眼
神經保護劑煙醯胺核苷治療青光眼的隨機對照試驗
神經保護劑煙醯胺核苷治療青光眼的隨機對照試驗
The study will randomize 125 patients with primary open-angle glaucoma (POAG) to receive an oral supplement of nicotinamide riboside 300 mg/day or a placebo (corn starch capsules) with an objective of comparing the rates of RNFL thinning (primary outcome measure) measured with a swept-source OCT over 24 months of follow-up between the treatment arms.
随机平行对照
其它
Patients will be randomized with minimization using a free open source computer program MinimPy to receive nicotinamide riboside 300 mg/day or a placebo (corn starch) at the baseline visit. Both the investigators and the patients will be blinded for the treatment assignment.
Both the investigators and the patients will be blinded for the treatment assignment.
Health and Medical Research Fund 2017
/
62;63
/
2019-04-01
2023-03-31
/
Age >=18 years; best corrected VA >=20/40; IOP <= 28mmHg; no history of laser procedure or intraocular surgery other than uncomplicated cataract extraction; patients with evidence of progressive RNFL/GCIPL thinning detected by Guided Progression Analysis(GPA) or Trend-based Progression Analysis (TPA)；
登录查看Pathological myopia; diseases that may cause visual field loss or optic disc abnormalities other than glaucoma; inability to perform reliable visual field; suboptimal quality of OCT images; and diabetic retinopathy/maculopathy; and a history of abnormal liver function.；
登录查看Research Fund Secretariat, Food and Health Bureau, The Government of HKSAR
/
精准药物2024-11-22
亚泰制药2024-11-22
医药时间2024-11-21
一度医药2024-11-21
新药创始人2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
细胞与基因治疗领域2024-11-21
药时空2024-11-21
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
